Our science is visionary.
Our commitment is relentless.
preserve vision and
prevent blindness.
About Us
Qlaris Bio is a clinical stage biotechnology company founded on a relentless commitment to develop innovative first-in-class therapies that can make a truly impactful change for patients suffering from serious and debilitating ophthalmic diseases.
Our Approach
We are exploring novel mechanisms of action to address the largest unmet needs in ophthalmology.
Our Science
Our lead asset, QLS-111, has a unique vasodilatory mechanism of action and is designed to lower intraocular pressure (IOP) by reducing episcleral venous pressure (EVP) and distal outflow resistance beyond the trabecular meshwork. By reducing EVP, and distal outflow resistance, QLS-111 has the potential to enable the achievement of lower IOP targets than available therapies currently allow.
QLS-111 is currently in development for the treatment of Normal Tension Glaucoma, Primary Open-Angle Glaucoma, Ocular Hypertension, and elevated IOP associated with rare diseases such as Sturge-Weber Syndrome.
Recent News See All News
Qlaris Bio Announces Positive Topline Data From Two Phase II Trials Of QLS-111 In Patients With Primary Open Angle Glaucoma And Ocular Hypertension
QLS-111 met all primary and secondary endpoints in the Osprey and Apteryx studies QLS-111 added to latanoprost drove up to 3.6 mmHg greater reduction in IOP as compared to latanoprost alone DEDHAM, Mass. — February 5, 2025 — Qlaris Bio, Inc., a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced positive topline results […]
Qlaris Bio Completes $24 Million Series B Financing Round to Advance QLS‑111, a First-in-class IOP-lowering Drug Candidate for Glaucoma
Financing led by Canaan and New Leaf Venture Partners, and includes funds managed by abrdn Inc., Correlation Ventures, and Mayo Clinic Ventures DEDHAM, Mass. — April 30, 2024 — Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced that it has closed a $24 million Series B financing round. […]